ZOETIS INC (ZTS) Stock Price, Forecast & Analysis
NYSE:ZTS • US98978V1035
ZTS Key Statistics, Chart & Performance
The current stock price of ZTS is 126.65 USD. In the past month the price increased by 1.09%. In the past year, price decreased by -19.6%.
ZTS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to ZTS. When comparing the yearly performance of all stocks, ZTS is a bad performer in the overall market: 75.69% of all stocks are doing better.
ZTS Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to ZTS. ZTS gets an excellent profitability rating and is at the same time showing great financial health properties.
ZTS Financial Highlights
Over the last trailing twelve months ZTS reported a non-GAAP Earnings per Share(EPS) of 6.42. The EPS increased by 8.45% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 28.21% | ||
| ROA | 17.49% | ||
| ROE | 49.11% | ||
| Debt/Equity | 1.31 |
ZTS Forecast & Estimates
24 analysts have analysed ZTS and the average price target is 159.46 USD. This implies a price increase of 25.91% is expected in the next year compared to the current price of 126.65.
For the next year, analysts expect an EPS growth of 6.97% and a revenue growth 5.01% for ZTS
ZTS Ownership
ZTS Latest News, Press Relases and Analysis
ZTS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 30.99 | 983.195B | ||
| JNJ | JOHNSON & JOHNSON | 20.9 | 586.544B | ||
| MRK | MERCK & CO. INC. | 22.44 | 301.342B | ||
| PFE | PFIZER INC | 9.18 | 156.812B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 9.98 | 123.651B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 8.71 | 26.086B | ||
| VTRS | VIATRIS INC | 6.23 | 18.163B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.04 | 12.486B | ||
| AXSM | AXSOME THERAPEUTICS INC | 221.27 | 9.135B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the New York Stock Exchange Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About ZTS
Company Profile
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,500 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Company Info
ZOETIS INC
10 Sylvan Way
Parsippany NEW JERSEY 07054 US
CEO: Kristin C. Peck
Employees: 14500
Phone: 13026587581
ZOETIS INC / ZTS FAQ
What does ZOETIS INC do?
Zoetis, Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health technology. The company is headquartered in Parsippany, New Jersey and currently employs 14,500 full-time employees. The company went IPO on 2013-02-01. The firm is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The firm operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. The company directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The firm is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
Can you provide the latest stock price for ZOETIS INC?
The current stock price of ZTS is 126.65 USD. The price increased by 0.8% in the last trading session.
Does ZOETIS INC pay dividends?
ZOETIS INC (ZTS) has a dividend yield of 1.64%. The yearly dividend amount is currently 1.73.
What is the ChartMill technical and fundamental rating of ZTS stock?
ZTS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
How is the valuation of ZOETIS INC (ZTS) based on its PE ratio?
The PE ratio for ZOETIS INC (ZTS) is 19.73. This is based on the reported non-GAAP earnings per share of 6.42 and the current share price of 126.65 USD.
Can you provide the number of employees for ZOETIS INC?
ZOETIS INC (ZTS) currently has 14500 employees.
What is the next earnings date for ZTS stock?
ZOETIS INC (ZTS) will report earnings on 2026-05-04, before the market open.